跳至主要内容
临床试验/CTRI/2008/091/000074
CTRI/2008/091/000074已完成2 期

Small intestine bacterial overgrowth and role of probiotic, VSL#3 in patients with nonalcoholic fatty liver disease

CD Pharma India Pvt Ltd0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Patients with raised liver enzymes (AST/ALT) at least 1.5 times the normal for more than three months
  • 2.No history of alcohol intake or intake less than 20g/d (to be confirmed from at least two family members)
  • 3.Negative viral markers (HBsAg and anti HCV)
  • 4.Negative autoimmune markers (anti nuclear anti bodies (ANA), anti smooth muscle antibody (ASMA), anti liver kidney microsomal antibody (anti LKM), antimitochondrial antibody (AMA)
  • 5.Normal ceruloplasmin
  • 6.Negative KF ring
  • 7.Normal iron studies
  • 8.Liver biopsy consistent with features of NAFLD

排除标准

  • 1.Pregnant females
  • 2.Patients with diabetes mellitus
  • 3.Patients with cirrhosis on imaging or liver biopsy
  • 4.Patients with history of drug intake likely to cause NAFLD (e.g. corticosteroids, methotrexate, tamoxifen etc)

研究者

相似试验